Aura Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aura Biosciences, Inc. - overview
Established
2009
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Aura Biosciences, Inc. is a Boston-based company focused on developing targeted oncology therapies, leveraging its proprietary Virus-Like Drug Conjugate technology to treat rare cancers such as choroidal melanoma. Founded in 2009 in Boston, US, Aura Biosciences, Inc. specializes in innovative oncology treatments.
The company is led by CEO Elisabet de los Pinos. Its recent funding round on May 14, 2025, raised USD 75 mn, bringing the total amount raised to USD 75 mn across 16 deals. Aura Biosciences develops targeted therapies in oncology, utilizing its Virus-Like Drug Conjugate (VDC) technology. Its leading product, Belzupacap sarotalocan, targets early-stage choroidal melanoma.
The company is also expanding its pipeline to include therapies for choroidal metastasis and bladder cancer, primarily serving oncologists and healthcare institutions in the US and Europe. Aura Biosciences generates revenue through partnerships with academic institutions and healthcare organizations, focusing on its VDC products. The business model targets B2B sales to hospitals and clinics, with revenue stemming from the sale of its VDCs and potential licensing agreements with pharmaceutical companies. In May 2025, Aura Biosciences raised USD 75 mn in a private placement, selling shares on Nasdaq.
The company plans to utilize this funding to advance its product pipeline, including the launch of new therapies targeting additional cancer indications, and to expand into European markets by 2026, addressing unmet medical needs in oncology.
Current Investors
Alexandria Venture Investments, Ysios Capital Partners, Lundbeckfond Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.aurabiosciences.com
Verticals
Nanotechnology
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aura Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.